jueves, 19 de enero de 2023

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer: an age‑specific subgroup analysis of MONARCH 2 and 3 trials – ePrintServer 2

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer: an age‑specific subgroup analysis of MONARCH 2 and 3 trials – ePrintServer 2

No hay comentarios:

Publicar un comentario